TechNews.com: MedImmunne

Daily Technology E-LETTER


	Technology Home

	Washtech

	Tech Policy

	Government IT

	Markets

	Columnists

	Personal Tech

	Special Reports

	Jobs

Thinking Big at MedImmune
CEO David Mott is leading MedImmune on an growth path he hopes will solidify the company's place among the world's top biotechs.

MedImmune

	• Stock Quote and News • Historical Chart • Company Description • Analyst Ratings

Washtech Companies

MedImmune Posts Loss Of $1.1 Billion in Quarter
MedImmune Inc., a Gaithersburg biotechnology company, yesterday reported a $1.1 billion loss as rising revenue was offset by one-time charges related to its acquisition of a California vaccine firm.

In the News
Acquisition Boosts MedImmune Loss (Post, April 25, 2002; 3:10 PM)

MedImmune Expands Cancer Research (Post, April 22, 2002)

MedImmune's Pain-Free Ambitions: If Approved by the FDA, FluMist Would Become First Vaccine Delivered as a Nasal Spray (Post, March 18, 2002)

MedImmune to Acquire Aviron: Md. Firm to Gain Rights to Nasal-Spray Flu Vaccine (Post, Dec. 4, 2001)

Scientists in Search Of a Breakthrough (Post, Oct. 22, 2001)

MedImmune Posts Loss As Drug's Sales Decline (Post, Oct. 19, 2001)

MedImmune to Reacquire Drug Rights Early (Post, Sept. 11, 2001)

MedImmune May Help Firm Produce Drug (Post, Aug. 16, 2001)

MedImmune Testing Drug (Post, Aug. 7, 2001)

MedImmune Reports a Wider Loss (Post, July 26, 2001)

MedImmune Searching for a Winner: Gaithersburg Firm Begins Human Trials on Cancer Drug Vitaxin (Post, July 17, 2001)

MedImmune To Build New Campus: County, State Use Grants To Persuade Firm to Stay (Post, May 8, 2001)

MedImmune Profit Up 177%, Thanks To Virus Drug (Post, April 20, 2001)

© 2002, 2003 The Washington Post Company

Company Postings: Quick Quotes | Tech Almanac
About TechNews.com | Advertising | Contact TechNews.com | Privacy
My Profile | Rights & Permissions | Subscribe to print edition | Syndication

		SEARCH: Search Options